Literature DB >> 2416331

Tofisopam and midazolam: differences in clinical effects and in changes of CSF monoamine metabolites.

M Hovi-Viander, J Kanto, H Scheinin, M Scheinin.   

Abstract

The effect of two repeated oral doses of 100 mg tofisopam 15 mg midazolam and placebo on the concentrations of monoamine metabolites (MHPG, 5-HIAA, HVA) in lumbar CSF were studied in general surgical patients operated on under spinal analgesia (n = 12 in each group). Midazolam, but not tofisopam, improved the quality of sleep the night before surgery. Both active agents reduced preoperative anxiety of the patients, but tofisopam was without subjective sedative action. In the placebo group, in contrast to the active drug groups, there was a slight positive correlation between the MHPG concentration and degree of anxiety before surgery. The only significant difference in the monoamine metabolites in lumbar CSF was found in the concentrations of HVA between tofisopam and placebo treated patients. The lower HVA concentrations suggest that the curious 3,4-benzodiazepine derivative, tofisopam, modifies central dopaminergic activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2416331      PMCID: PMC1400718          DOI: 10.1111/j.1365-2125.1985.tb05105.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

Review 1.  Molecular mechanisms in the receptor action of benzodiazepines.

Authors:  E Costa; A Guidotti
Journal:  Annu Rev Pharmacol Toxicol       Date:  1979       Impact factor: 13.820

Review 2.  Benzodiazepines as oral premedicants.

Authors:  J Kanto
Journal:  Br J Anaesth       Date:  1981-11       Impact factor: 9.166

3.  Site of lumbar puncture influences levels of monoamine metabolites.

Authors:  C Nordin; B Siwers; L Bertilsson
Journal:  Arch Gen Psychiatry       Date:  1982-12

4.  Tofizopam: a benzodiazepine derivative without sedative effect.

Authors:  J Kanto; L Kangas; T Leppänen; M Mansikka; M L Sibakov
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-07

Review 5.  Pharmacology of midazolam.

Authors:  L Pieri; R Schaffner; R Scherschlicht; P Polc; J Sepinwall; A Davidson; H Möhler; R Cumin; M Da Prada; W P Burkard; H H Keller; R K Müller; M Gerold; M Pieri; L Cook; W Haefely
Journal:  Arzneimittelforschung       Date:  1981

6.  Comparison of midazolam and flunitrazepam for night sedation. A randomised double-blind study.

Authors:  S Sjövall; J Kanto; L Kangas; A Pakkanen
Journal:  Anaesthesia       Date:  1982-09       Impact factor: 6.955

7.  Increase in 3H-flunitrazepam binding in vitro and in vivo to rat brain benzodiazepine receptors by tofizopam, a 3,4-benzo-diazepine.

Authors:  V Saano; A Urtti; M M Airaksinen
Journal:  Pharmacol Res Commun       Date:  1981-01

8.  Bromocriptine treatment of depressive disorders. Clinical and biochemical effects.

Authors:  C Nordin; B Siwers; L Bertilsson
Journal:  Acta Psychiatr Scand       Date:  1981-07       Impact factor: 6.392

9.  Comparative study of the clinical effects of tofizopam, nitrazepam and placebo as oral premedication.

Authors:  A Pakkanen; J Kanto; L Kangas; M Mansikka
Journal:  Br J Anaesth       Date:  1980-10       Impact factor: 9.166

10.  Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine.

Authors:  D S Charney; G R Heninger; D E Redmond
Journal:  Life Sci       Date:  1983-07-04       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.